Health
Neutrolis announces development of first-in-class therapy to target NETs in COVID-19 patients – News-Medical.Net
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemica…
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.
We believe NETs are the common factor that explains the …
-
Noosa News24 hours agoDevastating update in search for missing Queensland mother Tayla Spies as police find human remains near her ute
-
General23 hours agoHousing affordability. The crisis the major parties are too scared to fix
-
General22 hours agoDon’t use defence as bargaining chip in US tariff negotiations, warns former PM John Howard
-
Noosa News22 hours agoPolice to get on-the-spot protection powers for DV victims